<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01143298</url>
  </required_header>
  <id_info>
    <org_study_id>LEO 27847-K01</org_study_id>
    <nct_id>NCT01143298</nct_id>
  </id_info>
  <brief_title>LEO 27847 - Single Dose Bioavailability Study of Oral Solution Versus Tablet in Healthy Subjects</brief_title>
  <official_title>LEO 27847 - A Single Dose Bioavailability Study of Oral Solid Dosage Form Versus Oral Solution Including Fed Versus Fasted State in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase 1 study is to determine the relative bioavailability following&#xD;
      single oral dose administration of LEO 27847 solution compared to LEO 27847 tablets in&#xD;
      healthy male subjects as well as to determine the effect of food on the single oral dose&#xD;
      pharmacokinetics of LEO 27847 tablets in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters</measure>
    <time_frame>7 weeks</time_frame>
    <description>AUC and Cmax in each group</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LEO 27847 oral solution 0.1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 27847 oral solution 0.1 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 27847 tablet 0.10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 27847 tablet 0.10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 27847 tablet 0.01 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 27847 tablet 0.01 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 27847 oral solution</intervention_name>
    <arm_group_label>LEO 27847 oral solution 0.1 mg</arm_group_label>
    <arm_group_label>LEO 27847 tablet 0.01 mg</arm_group_label>
    <arm_group_label>LEO 27847 tablet 0.10 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects will have given their written informed consent to participate in the study&#xD;
             and to abide by the study restrictions.&#xD;
&#xD;
          -  Subjects will be Caucasian males between 18 and 45 years of age, with body mass index&#xD;
             (BMI) between 18 and 32 kg/m2 inclusive.&#xD;
&#xD;
          -  Subjects will have a minimum weight of 50 kg&#xD;
&#xD;
          -  Subjects must be in good health, as determined by a medical history, physical&#xD;
             examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations&#xD;
             (congenital non haemolytic hyperbilirubinaemia is acceptable)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  male subjects who are not willing to use appropriate contraception (such as condom)&#xD;
             and for female partners; occlusive cap (diaphragm or cervical/vault caps) with&#xD;
             spermicidal foam/gel/film/cream/suppository) from the time of the first dose until 3&#xD;
             months after the final dosing occasion.&#xD;
&#xD;
          -  Subjects who have received any prescribed systemic or topical medication within 7 days&#xD;
             of the first dose administration unless in the opinion of the Investigator the&#xD;
             medication will not interfere with the study procedures or compromise safety&#xD;
&#xD;
          -  Subjects who have used any non-prescribed systemic or topical medication (including&#xD;
             herbal remedies) within 7 days of the first dose administration unless in the opinion&#xD;
             of the Investigator the medication will not interfere with the study procedures or&#xD;
             compromise safety&#xD;
&#xD;
          -  Subjects who have received any medications, including St John's Wort, known to&#xD;
             chronically alter drug absorption or elimination processes within 30 days of the first&#xD;
             dose administration unless in the opinion of the Investigator the medication will not&#xD;
             interfere with the study procedures or compromise safety&#xD;
&#xD;
          -  Subjects who are still participating in a clinical study (e.g. attending follow-up&#xD;
             visits) or who have participated in a clinical study involving administration of an&#xD;
             investigational drug (new chemical entity), or a marketed drug within the past 3&#xD;
             months prior to the first dosing occasion.&#xD;
&#xD;
          -  Subjects who have donated any blood, plasma or platelets in the month prior to&#xD;
             screening or who have made donations on more than two occasions within the 12 months&#xD;
             preceding the first dose administration&#xD;
&#xD;
          -  Subjects with a significant history of drug allergy as determined by the Investigator&#xD;
&#xD;
          -  Subjects who have any clinically significant allergic disease (excluding non-active&#xD;
             hay fever) as determined by the Investigator&#xD;
&#xD;
          -  Subjects who have a supine blood pressure and supine pulse rate at screening higher&#xD;
             than 140/90 mmHg and 100 beats per minute (bpm), respectively, or lower than 90/50&#xD;
             mmHg and 45 bpm, respectively, confirmed by repeat&#xD;
&#xD;
          -  Subjects who consume more than 28 units of alcohol per week or who have a significant&#xD;
             history of alcoholism or drug/chemical abuse as determined by the Investigator&#xD;
&#xD;
          -  Subjects who smoke, or who have smoked within 3 months prior to first dose&#xD;
             administration&#xD;
&#xD;
          -  Subjects with, or with a history of, any clinically significant neurological,&#xD;
             gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic,&#xD;
             endocrine, haematological, dermatological or other major disorders as determined by&#xD;
             the Investigator&#xD;
&#xD;
          -  Subjects who have had a clinically significant illness within 4 weeks of the start of&#xD;
             dose administration as determined by the Investigator&#xD;
&#xD;
          -  Subjects who are known to have hepatitis, or who are carriers of the hepatitis B&#xD;
             surface antigen (HBsAg) or hepatitis C antibody, or who have a positive result to the&#xD;
             test for HIV&#xD;
&#xD;
          -  Subjects who, in the opinion of their General Practitioner (GP) or the Investigator,&#xD;
             should not participate in the study, including subjects suspected for whatever reason&#xD;
             of not being able to comply with the requirements of the protocol&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashley Brooks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Ltd.</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>June 1, 2010</study_first_submitted>
  <study_first_submitted_qc>June 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2010</study_first_posted>
  <last_update_submitted>December 10, 2013</last_update_submitted>
  <last_update_submitted_qc>December 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

